Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy

American Journal of Transplantation

Volumn 6, Issue 11, 2006, Pages 2750-2758

  Gleissner, C A ^a   Doesch, A ^a   Ehlermann, P ^a   Koch, A ^a   Sack, F U ^a   Katus, H A ^a   Dengler, T J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Heart transplant patients; Immunosuppression; Rapamycin; Renal function

Indexed keywords

CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; APHTHOUS ULCER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG EMBOLISM; MALE; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RENAL PROTECTION; RISK ASSESSMENT; SKIN PRURITUS; THROMBOEMBOLISM;

ADULT; AGED; BLOOD PRESSURE; CHOLESTEROL; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART TRANSPLANTATION; HEMOGLOBINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PLATELET COUNT; PROTEINURIA; SIROLIMUS; TRIGLYCERIDES;

EID: 33750011166     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01527.x     Document Type: Article

References (27)

1. Hosenpud JD, Novick RJ, Breen TJ, Keck B, Daily P. The registry of the international society for heart and lung transplantation: Twelfth official report - 1995. J Heart Lung Transplant 1995; 14: 805-815.
2. Greenberg A, Thompson ME, Griffith BJ et al. Cyclosporine nephrotoxicity in cardiac allograft patients - a seven-year follow-up. Transplantation 1990; 50: 589-593.
3. Waser M, Maggiorini M, Binswanger U et al. Irreversibility of cyclosporine-induced renal function impairment in heart transplant recipients. J Heart Lung Transplant 1993; 12: 846-850.
4. Sehgal V, Radhakrishnan J, Appel GB, Valeri A, Cohen DJ. Progressive renal insufficiency following cardiac transplantation: Cyclosporine, lipids, and hypertension. Am J Kidney Dis 1995; 26: 193-201.
5. Goldstein DJ, Zuech N, Sehgal V, Weinberg AD, Drusin R, Cohen D. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: Incidence and progression. Transplantation 1997; 63: 664-668.
6. Al Aly Z, Abbas S, Moore E, Diallo O, Hauptman PJ, Bastani B. The natural history of renal function following orthotopic heart transplant. Clin Transplant 2005; 19: 683-689.
7. Puschett JB, Greenberg A, Holley J, McCauley J. The spectrum of ciclosporin nephrotoxicity. Am J Nephrol 1990; 10: 296-309.
8. Bertani T, Ferrazzi P, Schieppati A et al. Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int 1991; 40: 243-250.
9. Sanchez V, Delgado JF, Morales JM et al. Chronic cyclosporine-induced nephrotoxicity in heart transplant patients: Long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 2004; 36: 2823-2825.
10. Angermann CE, Stork S, Costard-Jackle A et al. Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients - the IMPROVED multi-centre study. Eur Heart J 2004; 25: 1626-1634.
11. Groetzner J, Kaczmarek I, Meiser B, Muller M, Daebritz S, Reichart B. Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure. J Heart Lung Transplant 2004; 23: 770-773.
12. Vazquez de Prada JA, Vilchez FG, Cobo M et al. Sirolimus in de novo heart transplant recipients with severe renal impairment. Transpl Int 2006; 19: 245-248.
13. Snell GI, Levvey BJ, Chin W et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002; 21: 540-546.
14. De Meester JM, Van Vlem B, Walravens M et al. Preservation of renal function after heart transplantation: Initial single-center experience with sirolimus. Transplant Proc 2005; 37: 1835-1838.
15. Lobach NE, Pollock-Barziv SM, West LJ, Dipchand AI. Sirolimus immunosuppression in pediatric heart transplant recipients: A single-center experience. J Heart Lung Transplant 2005; 24: 184-189.
16. Fernandez-Valls M, Gonzalez-Vilchez F, de Prada JA, Ruano J, Ruisanchez C, Martin-Duran R. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: Experience of a single center. Transplant Proc 2005; 37: 4021-4023.
17. Hunt J, Lerman M, Magee MJ, Dewey TM, Herbert M, Mack MJ. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. J Heart Lung Transplant 2005; 24: 1863-1867.
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
19. Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003; 3: 534-542.
20. Parada B, Mota A, Nunes P et al. Calcineurin inhibitor-free immunosuppression in renal transplantation. Transplant Proc 2005; 37: 2759-2761.
21. Watson CJE, Firth J, Williams PF et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005; 5: 2496-2503.
22. Mancini D, Pinney S, Burkhoff D et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48-53.
23. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858.
24. Vu MD, Qi S, Xu D et al. Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Transplantation 1998; 66: 1575-1580.
25. Charpentier B, Groth CG, Backman L et al. Bicetre hospital experience with sirolimus-based therapy in human renal transplantation: The Sirolimus European Renal Transplant Study. Transplant Proc 2003; 35(3 Suppl): 58S-61S.
26. Peddi VR, Jensik S, Pescovitz M et al. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant 2005; 19: 130-136.
27. Straathof-Galema L, Wetzels JF, Dijkman HB, Steenbergen EJ, Hilbrands LB. Sirolimus-associated heavy proteinuria in a renal transplant recipient: Evidence for a tubular mechanism. Am J Transplant 2006; 6: 429-433.